Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach.

Dispenzieri, A., Rajkumar, S.V., Gertz, M.A., Fonseca, R., Lacy, M.Q., Bergsagel, P.L., Kyle, R.A., Greipp, P.R., Witzig, T.E., Reeder, C.B., Lust, J.A., Russell, S.J., Hayman, S.R., Roy, V., Kumar, S., Zeldenrust, S.R., Dalton, R.J. & Stewart, A.K. (2007) Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clinic Proceedings, 82, 323–341. Harousseau, J.-L., Attal, M. & Avet-Loiseau, H. (2009) The role of complete response in multiple myeloma. Blood, 114, 3139–3146. Jakubowiak, A., Dytfeld, D., Griffith, K.A., Lebovic, D., Vesole, D., Jagannath, S., Al-Zoubi, A., Anderson, T., Nordgren, B., Detweiler-Short, K., Stockerl-Goldstein, K., Asra Ahmed, A., Jobkar, T., Durecki, D.E., McDonnell, K., Mietzel, M., Couriel, D., Kaminski, M. & Vij, R. (2012) A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood, 120, 1801–1809. Khan, M.L., Reeder, C.B., Kumar, S.K., Lacy, M.Q., Reece, D.E., Dispenzieri, A., Gertz, M.A., Greipp, P., Hayman, S., Zeldenhurst, S., Dingli, D., Lust, J., Russell, S., Laumann, K.M., Mikhael, J.R., Leif Bergsagel, P., Fonseca, R., Vincent Rajkumar, S. & Keith Stewart, A. (2012) A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. British Journal of Haematology, 156, 326–333. Kumar, S.K., Rajkumar, S.V., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Zeldenrust, S.R., Dingli, D., Russell, S.J., Lust, J.A., Greipp, P.R., Kyle, R.A. & Gertz, M.A. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 2516–2520. Kumar, S., Flinn, I., Richardson, P.G., Hari, P., Callander, N., Noga, S.J., Stewart, A.K., Turturro, F., Rifkin, R., Wolf, J., Estevam, J., Mulligan, G., Shi, H., Webb, I.J. & Rajkumar, S.V. (2012) Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood, 119, 4375–4382. Reeder, C.B., Reece, D.E., Kukreti, V., Chen, C., Trudel, S., Hentz, J., Noble, B., Pirooz, N.A., Spong, J.E., Piza, J.G., Zepeda, V.H., Mikhael, J.R., Leis, J.F., Bergsagel, P.L., Fonseca, R. & Stewart, A.K. (2009) Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia, 23, 1337–1341. Reeder, C.B., Reece, D.E., Kukreti, V., Chen, C., Trudel, S., Lauman, K., Hentz, J., Pirooz, N.A., Piza, J.G., Tiedemann, R., Mikhael, J.R., Leis, J.F., Bergsagel, P.L., Fonseca, R. & Stewart, A.K. (2010) Onceversus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood, 115, 3416– 3417. Richardson, P., Weller, E., Lonial, S., Jakubowiak, A., Jagannath, S., Raje, N., Avigan, D., Xie, W., Ghobrial, I., Schlossman, R., Mazumder, A., Munshi, N., Vesole, D., Joyce, R., Kaufman, J., Doss, D., Warren, D., Lunde, L., Kaster, S., DeLaney, C., Hideshima, T., Mitsiades, C., Knight, R., Esseltine, D. & Anderson, K. (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy inpatients with newly diagnosed multiple myeloma. Blood, 116, 679–686. Srivastava, G., Rana, V., Lacy, M.Q., Buadi, F.K., Hayman, S.R., Dispenzieri, A., Gertz, M.A., Dingli, D., Zeldenrust, S., Russell, S., McCurdy, A., Kapoor, P., Kyle, R., Rajkumar, S.V. & Kumar, S. (2013) Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. Leukemia, 27, 2062–2066.